The potential of carboxypeptidase G2: antibody conjugates as anti-tumour agents. II. In vivo localising and clearance properties in a choriocarcinoma model. by Melton, R. G. et al.
Br. J. Cancer (1990), 61, 420 424 © Macmillan Press Ltd.,
The potential of carboxypeptidase G2: antibody conjugates as anti-tumour
agents. II. In vivo localising and clearance properties in a choriocarcinoma
model
R.G. Melton', F. Searle2, R.F. Sherwood', K.D. Bagshawe2 & J.A. Boden2
'Division ofBiotechnology, PHLS Centrefor Applied Microbiology and Research, Porton Down, Salisbury, Wilts. SP4 OJG, UK;
and 2Department ofMedical Oncology, Charing Cross Hospital, Fulham Palace Road, London W6 8RF, UK.
Summary The in vivo localising and clearance properties of conjugates of the folate-degrading enzyme
carboxypeptidase G2 (CPG2) with anti-human chorionic gonadotrophin (W14A) were measured in nude mice
bearing CC3 choriocarcinoma xenografts. Conjugates ofW14A-F (ab')2 fragment coupled to CPG2 localised in
tumour as effectively as native antibody alone but showed lower uptake in other major tissues. The clearance
rates of conjugates prepared with intact antibody or F (ab')2 fragment were shown to be up to five-fold faster
than for native antibody and two-fold compared to F (ab')2 fragment. Molecular weight analysis of residual
conjugate in the blood showed that no degradation of conjugate to its component molecules occurred during
circulation. It was concluded that F (ab')2: CPG2 conjugates offered the greatest potential for targeting
applications.
When antibodies directed at tumour-associated antigens are
injected intravenously, they tend to clear slowly from the
vascular compartment and the most favourable tumour to
normal tissue discrimination is achieved only after several
days (Begent, 1985). Attempts to use antibodies as vectors
for cytotoxic substances are severely handicapped by these
characteristics. It has been suggested that antibodies might
prove more satisfactory as vectors for enzymes which could
be used to deplete essential metabolites or to activate subse-
quently administered prodrugs (Bagshawe, 1983, 1987).
An antibody-enzyme conjugate exploits the retention at the
tumour site, with an increasing differential effect as the bulk
of the conjugate clears from the bloodstream. The greatest
cumulative metabolite depletion should, therefore, occur
within the tumour. The conjugate can act extracellularly,
removing the need for specific internalisation of its com-
ponents into tumour cells to exert a cytotoxic effect.
Clearance through the reticuloendothelial system with deg-
radation by lysosomal proteinases should protect the liver
and spleen from damage during passage.
The folate-degrading enzyme, carboxypeptidase G2 (CPG2),
provides a good model to study the feasibility of tumour-
localised metabolite depletion in vivo. The enzyme has been
shown to inhibit growth of a number of tumour cell lines in
vitro (Bertino et al., 1971) and the Walker 256 adeno-
carcinoma in vivo (R.F. Sherwood and C.N. Wiblin, unpub-
lished results). Experiments using erythroleukaemia cells
suggest that a 10-30-fold reduction in intracellular folate is
required before cell replication is prevented (Steinberg et al.,
1983). To achieve and maintain such a degree of folate
depletion using CPG2 alone, against a background of con-
tinual repletion from dietary and hepatic sources may require
prolonged dosage with the enzyme. However, CPG2 has been
shown to have an additive effect when used in conjuction
with non-classical folate analogues lacking the terminal
glutamate residue of folic acid, and which are not, therefore,
substrates for the enzyme (Kalghatgi et al., 1977; J.R. Ber-
tino, personal communication). In view of this potential app-
lication and its use of an activator of pro-drugs, we have
studied the persistence and fate of conjugates of CPG2 with
anti-human chorionic gonadotrophin (anti-hCG) or its
F (ab')2 fragment as a means of selectively delivering the
enzyme to CC3 choriocarcinoma xenografts borne by nude
mice and rats (Searle et al., 1981).
Materials and methods
CPG2 was prepared by the Division of Biotechnology,
CAMR, Porton Down, UK, following a previously described
protocol (Sherwood et al., 1985). Immunopurified mouse
monoclonal W14A anti-human chorionic gonadotrophin and
F (ab')2 fragments of the same antibody were produced by
previously described methods (Searle et al., 1984, 1986b) by
the Department of Medical Oncology, Charing Cross Hos-
pital, London, UK.
Preparation ofconjugates ofCPG2 with W14A and F (ab')2
fragment
1251- or '3'I-labelled CPG2 was produced using the
Chloramine T method (Hunter & Greenwood, 1962). 'l3I-
labelled W14A or F (ab')2 were produced by a modification
of the same method in which the reduction of free iodide to
iodine by sodium metabisulphite was replaced by the addi-
tion of L-tyrosine (100jld of a freshly prepared solution,
2 mg ml-' in PBS). This modification to the method has been
reported to result in less immunological deterioration of the
antibody (Searle et al., 1984)
Conjugates of radiolabelled CPG2 and W14A or its
F (ab')2 fragment were prepared using MBS heterobifunc-
tional reagent by previously described techniques (Searle et
al., 1986a). The conjugates were purified by gel filtration
chromatography on a column (2.2 x 90 cm) of Ultrogel
AcA34, with PBS as elution buffer. Fractions containing
conjugate were pooled, concentrated, filter sterilised and
stored at 4°C until used for animal experiments. A sample of
the isolated product was assayed by analytical gel filtration
on a column (HRIO/30) of Superose 12.
The immunoreactivity of the conjugates was assessed by an
indirect ELISA method, which permitted measurement of the
antigen binding capacity of radiolabelled conjugate. Con-
jugate bound to hCG-coated 96 well plates was measured by
goat anti-mouse-F (ab')2: peroxidase (Sigma), irrespective of
whether conjugate was constructed with intact W14A or
F (ab')2 fragment, using intact W14A as standard. Typically,
radiolabelled W14A and F (ab')2 conjugates showed greater
than 90% retention of full antigen binding capacity.
Distribution of W14A: CPG2 and F (ab')2: CPG2 conjugates
Groups of four male nude mice bearing CC3 choriocar-
cinoma xenograft tumours on the flank (200-900 mg
tumours) were given i.v. injections of approximately 3fiCi of
MBS-linked W14A: '251I-CPG2, (14 lg protein) or F(ab')2:
'25I-CPG2 (9 ;g protein) in 0.5 ml PBS. The animals were
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killed at 24 h intervals for the excision of tissue samples,
which were weighed, dissolved in 6 M potassium hydroxide to
a standard volume (Presman & Korngold, 1953) and counted
in an LKB 'Compugamma' counter. The results of the
experiments were calculated as the mean c.p.m g-' tissue and
expressed as percentage of the injected dose with standard
deviation.
Clearance of W14A, W14A-F (ab')2fragment and their
respective conjugates with CPG2
Groups of four male nude mice bearing CC3 choriocar-
cinoma xenografts on the flank (200- 900 mg tumours) were
given i.v. injections of approximately 3 giCi of 1251-W14A,
(10 gig) 125I-F (ab')2 (7 gLg) or dual labelled, MBS-linked 13I'-
W14A: 125I-CPG2 (14 jig); '311-F (ab')2: 1251-CPG2 (9 gig) (3 giCi
of each label) in 0.5 ml PBS. Serial blood samples were
collected over a 32 h period from the tail vein and delivered
into microcentrifuge tubes containing 40 gl PBS. The entire
contents were counted in an LKB model 1270 'Rackgamma'
counter for the determination of 1251 and 131I activities.
Molecular weight analysis ofblood samples by gelfiltration
Groups of four male mice bearing CC3 choriocarcinoma
xenografts on the flank (200-900 mg tumours) were given
i.v. injections of approximately 3 liCi of '31I-W14A, '3'I-
F (ab')2, MBS-linked '31I-W14A: '251I-CPG2, or MBS-linked
31l-F (ab')2: 125I-CPG2 in 0.5ml PBS. Blood samples were
collected by cardiac puncture from pairs of animals 12 and
24 h after injection and pooled. The samples were centrifuged
at 3,000 g to sediment red cells and samples (200 gl) of
plasma analysed by gel filtration using an FPLC apparatus
fitted with a Superose 12 column (1.0 x 30 cm) (Pharmacia,
Uppsala, Sweden). Fractions (1 ml) were collected and
counted as above.
Results
Preparation ofconjugate
The elution profile of a crude preparation of dual-labelled
W14A:CPG2 following gel filtration chromatography on a
column of Ultrogel AcA 34 is shown in Figure la. The
fractions containing activity associated with both CPG2 and
W14A and corresponding in molecular weight to that of 1:1
conjugate were pooled for use in animal experiments. A
sample of this pool was subjected to analytical gel filtration,
using a calibrated Superose 12 column (HRIO/30). The elu-
tion profile (A280 trace) is shown in Figure lb; integration
analysis of the peak areas showed that the preparation con-
sisted of 75% 1:1 conjugate, the balance being primarily
uncoupled W14A with a small amount of uncoupled CPG2;
similar results (data not shown) were recorded for F (ab')2:
CPG2 conjugate.
The immunoreactivity of the conjugates and radiolabelled
immunoglobulins was measured by ELISA. Little deteriora-
tion of antigen-binding capacity was recorded, all samples
typically retaining greater than 90% ofthe binding activity of
the immunoglobulin from which they were constructed (in
the range 91-107% control titre). Similar results have been
reported for unlabelled conjugates, measured by radio-
immunoassay (Searle et al., 1986a).
Distribution of W14A:CPG2 and F (ab')2: CPG2 conjugates
Results of this experiment (after Pressman & Korngold,
1953) are presented in Table I, which includes control values
for free W14A and its F (ab')2 fragment.
After 24 h there was little difference in the tumour levels
recorded with native W14A or F (ab')2:CPG2 conjugate. As
expected, native F(ab')2 fragment showed a lower tumour
uptake, because of its rapid clearance from circulation, and
the tumour uptake of W14A:CPG2 was also low. Although
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Figure 1 a, Isolation of 1:1 W14A: CPG2 conjugate. A sample
of crude conjugate (2 ml) was loaded onto a column
(2.2 x 90 cm) of Ultrogel AcA34. Elution was with phosphate
buffered saline at a flow rate of 20 ml h-'. 3.0 ml fractions were
collected and 50 il samples assayed for 125I (U) and 131I (0)
activity. b, Analysis of the composition of isolated W14A:CPG2
conjugate. 200 1I of isolated conjugate was loaded onto a calib-
rated column (HRI0/30) ofSuperose 12. Elution was with PBS at
a flow rate of 0.5mlmin-'. Calibration markers: Ca-Catalase
(232,000 Da); W-W14A intact (150,000 Da); CP-CPG2 (83,000
Da).
Table I Tissue distribution ofWl4A, F (ab')2 fragment ofWl4A, and
their respective conjugates with CPG2 in nude mice bearing CC3
choriocarcinoma xenografts
% per g injected dose
Tissue Sample 24 hour 72 hour
Tumour W14A 1.48 ±0.53 0.85 ± 0.19
W14A:CPG2 0.23 ± 0.03 0.20 ± 0.02
F (ab')2 0.76 ± 0.31 0.29 ± 0.16
F (ab')2:CPG2 1.10 ± 0.47 0.70 ± 0.25
Liver W14A 0.98 ± 0.17 0.33 ± 0.03
W14A:CPG2 0.27 ± 0.07 0.10 ± 0.01
F (ab')2 0.33 ± 0.09 0.06 ± 0.01
F (ab')2:CPG2 0.34 ± 0.02 0.09 ± 0.04
Kidney W14A 0.60± 0.11 0.20± 0.03
W14A:CPG2 0.22 ± 0.04 0.07 ± 0.01
F (ab')2 0.35 ± 0.09 0.06 ± 0.01
F (ab')2:CPG2 0.37 ± 0.04 0.18 ± 0.13
Lung W14A 0.70 ± 0.14 0.24± 0.03
W14A:CPG2 0.33 ± 0.05 0.12± 0.07
F (ab')2 0.30 ± 0.08 0.04 ± 0.01
F (ab')2:CPG2 0.35 ± 0.09 0.07 ± 0.03
Spleen W14A 0.57 ± 0.05 0.18 ± 0.05
W14A:CPG2 0.20 ± 0.03 0.07± 0.10
F (ab')2 0.15 ± 0.02 0.02 ± 0.01
F (ab')2:CPG2 0.19 ± 0.11 0.05 ± 0.06
Groupsoffourmicewereused,anddistribution ofsamplescalculated
as the percentage of injected dose per gram of tumour with standard
deviation (n-1).
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there was pronounced retention of W14A in the liver, even at
72 h, there was much less uptake of W14A:CPG2, F (ab')2
and F (ab')2:CPG2. The pattern of uptake was generally
similar at 72 h, although total amounts for all tissues were
lower.
In general, native W14A accumulated and persisted in
other tissues to a larger extent than in conjugated form with
CPG2 or when compared with F (ab')2 fragment and its
conjugate. The encouraging conclusion was that
F (ab')2:CPG2 localised at the tumour site in equal measure
to native W14A, but without the widespread normal tissue
distribution, particularly in liver, providing quantitative
confirmation of the results of imaging experiments previously
reported (Melton et al., 1988).
Clearance of W14A, F(ab')2, WJ4A:CPG2, and F(ab')2.CPG2
from blood circulation
The clearance of '251-labelled W14A following i.v. injection
is presented in Figure 2a. Clearance was biphasic with
t112= 14.5 h and 27 h. Clearance of F (ab')2 was more
rapid (Figure 2b) with t12 = 4 h and 13 h. The clearance
curves of W14A:CPG2 and F(ab')2:CPG2 determined using
MBS-linked, dual-labelled conjugates (Figure 3a and b) also
show a biphasic pattern, but with faster clearance rates
(t1 2= 2.5 h and 11 h for the CPG2 component).
Although the components of the dual-labelled compounds
showed different curves for each component, the variations
largely arose in the early phases of clearance, and it is likely
that contaminating uncoupled immunoglobulin was respon-
sible, since the half lives of native W14A and F (ab')2 frag-
ment are longer than those of the conjugate. Since there is
little free CPG2 compared with immunoglobulin, the
clearance curve of the CPG2 component of conjugate is likely
to be representative of that ofconjugate assuming the linkage
is stable. More recent studies (P. Antoniw, personal com-
munication) also suggest that the radiolabel on CPG2 is not
as stable as that on immunoglobulin.
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Figure 3 Clearance of W14A: CPG2 and W14A-F (ab')2: CPG2
conjugates in nude mice carrying CC3 xenografts. Percentage of
injected, dual-labelled dose per ml blood is calculated as the
mean of results from groups of four mice. a, W14A: CPG2. A
'31-labelled antibody component; * '251-labelled enzyme compo-
nent. b, W14A-F (ab')2: CPG2. *'251-labelled antibody compo-
nent; * '251-labelled enzyme component.
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The result shows that despite more rapid clearance of
conjugates, even compared with native F (ab')2, tumour
localisation is equivalent to that achieved with W14A. More
rapid clearance appears an advantage in reducing the more
general tissue distribution encountered with W14A.
Molecular weight analysis ofbloodsamples
The elution profiles of dual-labelled MBS-linked
W14A:CPG2 and F (ab')2:CPG2 in plasma 12 h after injection
are shown in Figure 4a and b respectively. There was no
difference in the elution position of the enzyme and antibody
32 labels within the conjugate. The position of W14A:CPG2
corresponded to 242,000 daltons (catalase standard) and
would be predicted for a 1:1 conjugate. F (ab')2:CPG2 eluted
just before native W14A (150,000 Da) also indicating a 1:1
ratio to give a conjugate of 180,000 Da. Similar results were
recorded for samples collected 24 h after injection (data not
shown) and no evidence of conjugate degradation during
circulation was recorded.
Discussion
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Figure 2 Clearance of WI4A and its F (ab'2)2 fragment in nude
mice carrying CC3 xenografts. Percentage of injected 1251 label
dose per ml blood is calculated as the mean of results from
groups of four mice. a, W14A intact; b, F(ab')2 fragment of
W14A.
Gamma-imaging studies had previously been performed as a
rapid method of assessing the ability of antibody: CPG2 con-
jugates to localise at solid tumours (Melton et al., 1988).
Conjugates labelled in the CPG2 moiety were used in order
that any localising effect determined could be attributed
unambiguously to localising of the conjugate and not the
antibody alone. The conjugate preparations contained only
low levels of uncoupled CPG2 and previous tissue distribu-
tion studies had shown that the native enzyme is cleared
from the circulation of experimental animals rapidly and
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Figure 4 Molecular weight analysis of dual-label '3.I-antibody:
'251-enzyme conjugate in plasma. Samples (200pi1) from two
animals were pooled and separated by size-exclusion FPLC on
Superose 12 calibrated with native enzyme (CP, 83,000 Da),
catalase (Ca, 232,000 Da) and native antibody (W, 150,000 Da).
a, intact WI4A: CPG2. *'3'I-labelled antibody; *'251I-labelled
enzyme. b, W14A-F (ab')2: CPG2. *'311-labelled antibody; .125I-
labelled enzyme.
does not accumulate to a marked extent in any tissue (Mel-
ton et al., 1987a, b). These results have also been confirmed
by imaging studies (Melton et al., 1988). It was demonstrated
that selective delivery of CPG2 to solid tumour could be
achieved in vivo when coupled to intact antibody and that the
enzyme, once delivered, was retained in the tumour over at
least a 3-day period. The degree of specificity obtained was
not high, with pronounced retention in the blood pool, and
evidence of liver uptake. In view of this, conjugates of CPG2
with F (ab')2 fragment of W14A were prepared. Coupling
CPG2 to F (ab')2 fragment was expected to offset the loss of
the 50 kDa Fc fragment and eliminate binding to Fc recep-
tors. The predicted reduction in non-tumour tissue uptake
was demonstrated and the effect confirmed in the tissue
distribution experiments. Tumour uptake of F (ab')2: CPG2
was equivalent to native W14A.
A number of other factors are known to influence levels of
uptake in labelled antibody by tumour cells in vivo. Uptake
has been shown to the inversely proportional to tumour
volume (Hagan et al., 1986), and also related to tumour
vascularity, antigen density and growth rates (Rostok et al.,
1985). The results reported here may have been influenced by
such factors, but our results do show that F(ab')2: CPG2
conjugates present advantages for targeting compared to con-
jugates prepared using intact antibody.
The localisation of W14A:CPG2 and F (ab')2 conjugates to
choriocarcinoma xenografts was particularly encouraging
because this tumour model is an unfavourable one for such
experiments. HCG antigen, shed into the circulation, and
providing the basis of the diagnosis and monitoring of
human choriocarcinoma (Bagshawe, 1980), would signal the
presence of tumour at serum levels far below those
encountered in these mouse studies (50-50,000 mIU ml-'
serum). Nevertheless, despite the strong possibility in our
model of the antigen-binding function of the conjugate being
neutralised by binding to circulating antigen, significant
differential retention at the tumour site has been achieved.
Comparison of our results with those reported by other
workers for antibody-toxin conjugates is complicated by a
number of factors. Antibody-toxin conjugates are commonly
constructed using disulphide or hindered disulphide linkages
(Worrell et al., 1986a). Although the short-term stability of
such conjugates does not appear to vary greatly from those
coupled with a thioether linkage, there does appear to be a
stability advantage in using thioether linkage if prolonged
stability of the conjugate is desired (Worrell et al., 1986a).
The postulated mechanism of action of CPG2 (enzyme
remaining extracellular and depleting the exogenous folate
supply) renders a stable linkage between enzyme and
antibody desirable. Conjugates containing the thioether link
prepared using the MBS reagent showed no evidence of
breakdown to component molecules for at least 12 hours
after injection and, whether described by labelled antibody or
labelled enzyme, the time courses ofconjugate clearance were
consistent with a stable linkage.
A further complicating factor with antibody: toxin con-
jugates is the presence of glycosyl residues on the toxins, for
example ricin has been shown to be susceptible to receptor
mediated-uptake due to mannose receptors present on non-
parenchymal cells in the liver interacting the mannose recep-
tors present on the ricin A chain (Worrell et al., 1986b).
As CPG2 is not glycosylated (Minton et al., 1984) this
form of hepatic clearance mechanism is not a likely comp-
lication, but, as already mentioned, antibody-antigen com-
plexes would tend to alter distribution of the anti-hCG-
bound enzyme towards the liver. It is evident that the exact
distribution of a given antibody-protein conjugate will be
determined by a number of competing physiological factors.
The results in this paper suggest that an MBS-linked con-
jugate of a non-glycosylated enzyme can be delivered to
target tumour cells even in the presence of large quantities of
circulating antigen, and that the conjugate possesses the
necessary stability to enable it to remain localised in the
vicinity of the target cells.
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